巴利昔单抗治疗激素难治性急性移植物抗宿主病的预后因素与长期随访:一项大规模研究的更新经验
该研究纳入230例异基因造血干细胞移植后激素难治性急性移植物抗宿主病患者,巴利昔单抗于第1、3、8天给药并每周重复至aGVHD低于II级或四剂无反应。多因素分析显示治疗前III-IV级aGVHD独立预测较差反应;II级与III-IV级患者14、28、56天总反应累积发生率分别为41.4% vs 23.1%(P=.023)、70.2% vs 43.6%(P=.002)、80.1% vs 66.7%(P=.013)。作者认为巴利昔单抗是安全有效的治疗。
要点
- 治疗前III-IV级aGVHD独立预测巴利昔单抗反应较差。
- II级与III-IV级aGVHD的56天总反应累积发生率为80.1% vs 66.7%(P=.013)。
- 接受超过四剂巴利昔单抗的患者感染率更高。
核心结论
- 巴利昔单抗是激素难治性急性移植物抗宿主病安全有效的治疗。
研究设计与样本
- 研究纳入1498例接受allo-HSCT患者中的230例SR-aGVHD患者,巴利昔单抗于第1、3、8天给药并每周重复至aGVHD低于II级或四剂无反应。
主要发现
- 多因素分析显示治疗前III-IV级aGVHD独立预测巴利昔单抗反应较差。
- II级与III-IV级aGVHD患者14天总反应累积发生率为41.4% vs 23.1%(P=.023)。
- II级与III-IV级aGVHD患者28天总反应累积发生率为70.2% vs 43.6%(P=.002)。
- II级与III-IV级aGVHD患者56天总反应累积发生率为80.1% vs 66.7%(P=.013)。
- 接受超过四剂巴利昔单抗的患者感染率更高。
关键数值与推荐
- 巴利昔单抗治疗后4年总慢性GVHD累积发生率为44.8%(95%CI 38.3%-51.3%)。
- 巴利昔单抗治疗后4年严重慢性GVHD累积发生率为2.2%(95%CI 0.3%-4.1%)。
- 巴利昔单抗治疗后4年复发累积发生率为11.3%(95%CI 7.2%-15.4%)。
- 巴利昔单抗治疗后4年非复发死亡累积发生率为30.0%(95%CI 24.1%-35.9%)。
- 巴利昔单抗治疗后4年无病生存累积发生率为58.7%(95%CI 52.3%-65.1%),总生存累积发生率为61.7%(95%CI 55.4%-68.0%)。
临床怎么用
- 移植前合并症及诊断时修订版Minnesota aGVHD风险评分显著影响长期生存。
- 接受超过四剂巴利昔单抗的患者感染率更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft-vs-host disease (aGVHD) is one of the most important causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly for those with steroid-refractory (SR)-aGVHD. We aimed to identify the prognostic factors and long-term clinical outcomes of basiliximab treatment for SR-aGVHD. Basiliximab was administered on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II, or patients showed no response after four doses. Out of 1498 patients receiving allo-HSCT, 230 patients with SR-aGVHD were enrolled. Grade III to IV aGVHD before basiliximab treatment significantly and independently predicted a poorer response to basiliximab in multivariate analysis. And, the cumulative incidence of overall response at 14 days, 28 days, and 56 days after treatment was 41.4% vs 23.1% (P = .023), 70.2% vs 43.6% (P = .002), and 80.1% vs 66.7% (P = .013), respectively. This was for those with grade II and grade III to IV aGVHD. Patients receiving more than four doses of basiliximab had higher rates of infections. The 4-year cumulative incidence of total and severe chronic GVHD after basiliximab treatment was 44.8% (95% CI 38.3%-51.3%) and 2.2% (95% CI 0.3%-4.1%), respectively. The 4-year cumulative incidence of relapse, non-relapse mortality, disease-free survival, and overall survival after basiliximab treatment was 11.3% (95% CI 7.2%-15.4%), 30.0% (95% CI 24.1%-35.9%), 58.7% (95% CI 52.3%-65.1%), and 61.7% (95% CI 55.4%-68.0%), respectively. Comorbidities before allo-HSCT and refined Minnesota aGVHD risk score at diagnosis had significant influences on long-term survival. Thus, basiliximab was a safe and effective treatment for patients with SR-aGVHD.
引用
- Liu SN, Zhang XH, Xu LP, et al. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study. Am J Hematol. 2020. PMID: 32311156. doi:10.1002/ajh.25839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。